SARS-CoV-2 vaccine candidates in rapid development

Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.

Abstract

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still spreading globally. The scientific community is attempting to procure an effective treatment and prevention strategy for COVID-19. A rising number of vaccines for COVID-19 are being developed at an unprecedented speed. Development platforms include traditional inactivated or live attenuated virus vaccines, DNA or RNA vaccines, recombinant viral vector vaccines, and protein or peptide subunit vaccines. There are 23 vaccines in the clinical evaluation stage and at least 140 candidate vaccines in preclinical evaluation. In this review, we describe research regarding basic knowledge on the virus, updates on the animal models, current landscape of vaccines in clinical evaluation and updated research results on vaccine development. Safe and effective COVID-19 vaccines require further investigation.

Keywords: COVID-19 pandemic; SARS-CoV-2; animal models; coronavirus; vaccine development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • COVID-19 / immunology*
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / immunology*
  • Humans
  • Pandemics / prevention & control
  • SARS-CoV-2 / immunology*

Substances

  • COVID-19 Vaccines

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China [31900116] and the Scientific and Technological Projects of Henan Province [202102310068 and 202102310395].